Matches in SemOpenAlex for { <https://semopenalex.org/work/W2604112126> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2604112126 endingPage "7207" @default.
- W2604112126 startingPage "7207" @default.
- W2604112126 abstract "7207 Background: The role of campthotecins in small cell lung cancer (SCLC) is emerging, and 5-day regimens with topetecan alone or with cisplatin have been shown to be active and tolerable. In order to provide a more feasible regimen for patients with extensive disease we developed a three-day regimen of topetecan and cisplatin. Preliminary data has previously been presented and we now present the final, updated results with a median follow-up time of 18 months. This investigators initiated study was supported by a grant from GlaxoSmithKline. Methods: This phase II study was planned to include 43 patients with histologically confirmed SCLC, extensive stage of disease, age 18–75 and WHO performance status 0–2. Patients received topetecan 2.0 mg/m2 on day 1–3 and cisplatin 50 mg/m2 on day 3, repeated every 3 weeks, for a maximum of 6 cycles. Patients with progressive disease (PD) or no-change (NC) after 3 cycles go off-study. Results: From May 2001 to September 2003, a total of 43 patients were included. An objective response has been observed in 74% (CR 16% and PR 58%). The regimen seems tolerable with no significant non-haematological toxicity. Until now there were no toxic deaths. Grade III and IV neutropenia was seen in 16% and 9%, respectively, and grade III and IV thrombocytopenia was observed in 3% and 3%, respectively. Non-hematological toxicity was mild. The median time to progression was 7.3 months (5.9–8.7), and the median survival time was 10.3 months (8.4–11.9). Conclusions: These updated results from this phase II study indicate this regimen is very active with limited toxicity. The data suggest that the efficacy and toxicity is similar to the 5-day schedule of topotecan and cisplatin. The schedule is attractive to patients with extensive stage SCLC and will now be evaluated in a phase III study. No significant financial relationships to disclose." @default.
- W2604112126 created "2017-04-14" @default.
- W2604112126 creator A5022463562 @default.
- W2604112126 creator A5034875580 @default.
- W2604112126 creator A5035087900 @default.
- W2604112126 creator A5049735840 @default.
- W2604112126 creator A5049829108 @default.
- W2604112126 creator A5050957961 @default.
- W2604112126 creator A5052742946 @default.
- W2604112126 creator A5063711128 @default.
- W2604112126 creator A5075591076 @default.
- W2604112126 creator A5083259679 @default.
- W2604112126 date "2004-07-15" @default.
- W2604112126 modified "2023-09-27" @default.
- W2604112126 title "A phase II study of a 3-day schedule with topotecan and cisplatin every three weeks in patients with previously in treated small cell lung cancer and extensive disease: Final results" @default.
- W2604112126 doi "https://doi.org/10.1200/jco.2004.22.90140.7207" @default.
- W2604112126 hasPublicationYear "2004" @default.
- W2604112126 type Work @default.
- W2604112126 sameAs 2604112126 @default.
- W2604112126 citedByCount "2" @default.
- W2604112126 crossrefType "journal-article" @default.
- W2604112126 hasAuthorship W2604112126A5022463562 @default.
- W2604112126 hasAuthorship W2604112126A5034875580 @default.
- W2604112126 hasAuthorship W2604112126A5035087900 @default.
- W2604112126 hasAuthorship W2604112126A5049735840 @default.
- W2604112126 hasAuthorship W2604112126A5049829108 @default.
- W2604112126 hasAuthorship W2604112126A5050957961 @default.
- W2604112126 hasAuthorship W2604112126A5052742946 @default.
- W2604112126 hasAuthorship W2604112126A5063711128 @default.
- W2604112126 hasAuthorship W2604112126A5075591076 @default.
- W2604112126 hasAuthorship W2604112126A5083259679 @default.
- W2604112126 hasConcept C126322002 @default.
- W2604112126 hasConcept C141071460 @default.
- W2604112126 hasConcept C2776256026 @default.
- W2604112126 hasConcept C2776694085 @default.
- W2604112126 hasConcept C2776907518 @default.
- W2604112126 hasConcept C2777063308 @default.
- W2604112126 hasConcept C2778239845 @default.
- W2604112126 hasConcept C2778822529 @default.
- W2604112126 hasConcept C2778850193 @default.
- W2604112126 hasConcept C2781209748 @default.
- W2604112126 hasConcept C2781413609 @default.
- W2604112126 hasConcept C29730261 @default.
- W2604112126 hasConcept C31760486 @default.
- W2604112126 hasConcept C71924100 @default.
- W2604112126 hasConcept C90924648 @default.
- W2604112126 hasConceptScore W2604112126C126322002 @default.
- W2604112126 hasConceptScore W2604112126C141071460 @default.
- W2604112126 hasConceptScore W2604112126C2776256026 @default.
- W2604112126 hasConceptScore W2604112126C2776694085 @default.
- W2604112126 hasConceptScore W2604112126C2776907518 @default.
- W2604112126 hasConceptScore W2604112126C2777063308 @default.
- W2604112126 hasConceptScore W2604112126C2778239845 @default.
- W2604112126 hasConceptScore W2604112126C2778822529 @default.
- W2604112126 hasConceptScore W2604112126C2778850193 @default.
- W2604112126 hasConceptScore W2604112126C2781209748 @default.
- W2604112126 hasConceptScore W2604112126C2781413609 @default.
- W2604112126 hasConceptScore W2604112126C29730261 @default.
- W2604112126 hasConceptScore W2604112126C31760486 @default.
- W2604112126 hasConceptScore W2604112126C71924100 @default.
- W2604112126 hasConceptScore W2604112126C90924648 @default.
- W2604112126 hasIssue "14_suppl" @default.
- W2604112126 hasLocation W26041121261 @default.
- W2604112126 hasOpenAccess W2604112126 @default.
- W2604112126 hasPrimaryLocation W26041121261 @default.
- W2604112126 hasRelatedWork W1975832547 @default.
- W2604112126 hasRelatedWork W1978453679 @default.
- W2604112126 hasRelatedWork W1990777236 @default.
- W2604112126 hasRelatedWork W2023128727 @default.
- W2604112126 hasRelatedWork W2128668224 @default.
- W2604112126 hasRelatedWork W2138054646 @default.
- W2604112126 hasRelatedWork W2225907637 @default.
- W2604112126 hasRelatedWork W2562333289 @default.
- W2604112126 hasRelatedWork W2592472299 @default.
- W2604112126 hasRelatedWork W2118693777 @default.
- W2604112126 hasVolume "22" @default.
- W2604112126 isParatext "false" @default.
- W2604112126 isRetracted "false" @default.
- W2604112126 magId "2604112126" @default.
- W2604112126 workType "article" @default.